Altimmune (ALT) Competitors

Biohaven has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Biohaven's return on equity.

Altimmune presently has a consensus target price of $15.71, indicating a potential upside of 459.23%. Biohaven has a consensus target price of $21.63, indicating a potential upside of 45.30%. Given Altimmune's stronger consensus rating and higher possible upside, research analysts plainly believe Altimmune is more favorable than Biohaven.

In the previous week, Biohaven had 2 more articles in the media than Altimmune. MarketBeat recorded 2 mentions for Biohaven and 0 mentions for Altimmune. Altimmune's average media sentiment score of 0.00 equaled Biohaven'saverage media sentiment score.

Altimmune has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Altimmune has higher revenue and earnings than Biohaven. Altimmune is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Comparatively, 13.8% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Altimmune has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Altimmune currently has a consensus price target of $15.71, suggesting a potential upside of 459.23%. Zai Lab has a consensus price target of $40.00, suggesting a potential upside of 94.93%. Given Altimmune's higher possible upside, research analysts clearly believe Altimmune is more favorable than Zai Lab.

Altimmune has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Zai Lab has a net margin of -39.29% compared to Altimmune's net margin of -214,860.98%. Zai Lab's return on equity of -24.32% beat Altimmune's return on equity.

In the previous week, Zai Lab had 1 more articles in the media than Altimmune. MarketBeat recorded 1 mentions for Zai Lab and 0 mentions for Altimmune. Zai Lab's average media sentiment score of 0.91 beat Altimmune's score of 0.00 indicating that Zai Lab is being referred to more favorably in the news media.

78.1% of Altimmune shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Pharvaris has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Pharvaris' return on equity.

In the previous week, Pharvaris had 6 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Pharvaris and 0 mentions for Altimmune. Pharvaris' average media sentiment score of 0.93 beat Altimmune's score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media.

Altimmune has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Altimmune currently has a consensus target price of $15.71, suggesting a potential upside of 459.23%. Pharvaris has a consensus target price of $50.08, suggesting a potential upside of 49.28%. Given Altimmune's higher probable upside, analysts plainly believe Altimmune is more favorable than Pharvaris.

Altimmune has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.34, indicating that its stock price is 334% less volatile than the broader market.

78.1% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ocular Therapeutix has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Ocular Therapeutix has a net margin of -558.24% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Ocular Therapeutix's return on equity.

In the previous week, Ocular Therapeutix had 4 more articles in the media than Altimmune. MarketBeat recorded 4 mentions for Ocular Therapeutix and 0 mentions for Altimmune. Ocular Therapeutix's average media sentiment score of 0.76 beat Altimmune's score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media.

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Altimmune has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Ocular Therapeutix presently has a consensus target price of $25.11, indicating a potential upside of 188.30%. Altimmune has a consensus target price of $15.71, indicating a potential upside of 459.23%. Given Altimmune's higher possible upside, analysts clearly believe Altimmune is more favorable than Ocular Therapeutix.